

1 PAUL D. TRIPODI II
State Bar No. 162380
ptripodi@wsgr.com
2 Wilson Sonsini Goodrich & Rosati P.C.
633 West Fifth Street, Suite 1550
3 Los Angeles, CA 90071
Telephone: 323-210-2900
4 Fax: 866-974-7329

5 NATALIE J. MORGAN
State Bar No. 211143
nmorgan@wsgr.com
6 Wilson Sonsini Goodrich & Rosati P.C.
12235 El Camino Real
7 San Diego, CA 92130
Telephone: 858-350-2300
8 Fax: 858-350-2399

9 WENDY L. DEVINE
State Bar No. 246337
wdevine@wsgr.com
10 Wilson Sonsini Goodrich & Rosati P.C.
One Market Plaza
11 Spear Tower, Suite 3300
San Francisco, California 94105-1126
12 Telephone: 415-947-2000
13 Fax: 415-947-2099

14 *Attorneys for Plaintiff NuVasive, Inc.*

15
16 **UNITED STATES DISTRICT COURT**
17 **SOUTHERN DISTRICT OF CALIFORNIA**
18 **SAN DIEGO DIVISION**

19 NUVASIVE, INC., a Delaware
20 corporation,
21 Plaintiff,
22 v.
23 ALPHATEC HOLDINGS, INC. and
ALPHATEC SPINE, INC., a Delaware
24 corporation,
25 Defendants.
26

CASE NO. 3:18-cv-00347-CAB-MDD

**DECLARATION OF
MATTHEW LINK IN SUPPORT
OF MOTION FOR
PRELIMINARY INJUNCTION**

Judge: Hon. Cathy Ann Bencivengo
Courtroom: 4C
Hearing Date: April 30, 2018

Jury Trial Demanded

REDACTED VERSION

27
28 DECLARATION OF MATTHEW LINK
ISO MOTION FOR PRELIMINARY
INJUNCTION

3:18-cv-00347-CAB-MDD

1 18. Each of the above described components – neuromonitoring
2 capabilities, specialized access tools, and specialized implants – were essential in
3 enabling NuVasive to become the first company to provide a safe, effective, and
4 reproducible minimally invasive lateral trans-psoas approach to the lumbar spine.

5 19. NuVasive debuted the XLIF procedure in October 2003 at the North
6 American Spine Society (“NASS”) Annual Meeting. Doc. No. 1-2 (IPR2014-
7 00075, July 8, 2014, Declaration of Patrick Miles) at 9. Despite the time, effort,
8 and cost NuVasive had put into developing the XLIF procedure, the majority of the
9 spinal surgery community was immediately skeptical. From the beginning, and
10 even during my first few years at the company, many surgeons did not believe that
11 spinal fusion surgery via a lateral, trans-psoas approach could be done safely and
12 reproducibly.

13 20. Members of the spinal community published their doubts regarding
14 the safety and efficacy of XLIF in the literature. For example, a 2003 article
15 explained that while surgeons recognized advantages to a lateral approach through
16 the psoas muscle, they “have not felt comfortable with dissecting the psoas because
17 of the presence of the lumbar plexus.” Ex. 5 (T. Moro, M.D., et al., *An Anatomic*
18 *Study of the Lumbar Plexus with Respect to Retroperitoneal Endoscopic Surgery*,
19 *Spine* Vol. 28, No. 5, pp. 423-428 (2003)) at 428. These misgivings regarding the
20 safety of traversing the psoas persisted through at least the 2009 timeframe, when
21 NuVasive’s internal market research demonstrated that some surgeons were still
22 concerned about “the perceived complications associated with XLIF (e.g., psoas
23 pain/weakness, dyesthesias, numbness, and quad weaknesses).” Ex. 6 (S. Craig
24 Meyer, M.D., *From the Proctor’s Perspective*, SOLAS News, Issue 10 (Apr.
25 2010)) at 3.

26 21. Other factors also hampered the initial adoption of XLIF, including
27 the fact that surgeons are generally reluctant to adopt new surgical techniques,

1 especially those for which they have had little training and require tools they are
2 not used to using.

3 22. NuVasive undertook considerable efforts to overcome these hurdles,
4 establishing a new lateral market in the process.

5 23. NuVasive initially focused on educating the spinal community that
6 XLIF was actually safe and effective, and training inexperienced surgeons how to
7 perform the XLIF procedure. At first, NuVasive partnered with the pioneers and
8 early adopters of XLIF to have them demonstrate the procedure and specialized
9 equipment in their own operating rooms to various inexperienced and skeptical
10 surgeons. One such surgeon was Dr. Luiz Pimenta in Brazil. Dr. Pimenta was the
11 surgeon who initially demonstrated a minimally invasive endoscopic lateral, trans-
12 psoas approach for spinal fusion to NuVasive in Brazil. He then worked with
13 NuVasive to develop its unique surgical tools and neuromonitoring that enabled
14 *reproducible* minimally invasive lateral, trans-psoas fusion surgery. Once the
15 inexperienced surgeons saw the XLIF technology in action, including in the
16 operating room of Dr. Pimenta himself, they felt far more comfortable using XLIF
17 in their own practices.

18 24. NuVasive also began utilizing the cadaver lab in its San Diego,
19 California headquarters as an XLIF surgeon training center. This facility, which
20 had been used to develop and clinically validate the viability of the XLIF solution,
21 now allowed NuVasive to demonstrate the benefits of XLIF to surgeons in a
22 hands-on environment. Facilitated by a team of experts, since 2005 through today,
23 the six-suite operating room and training facility is available for surgeons on
24 virtually a “24/7” basis. NuVasive also implemented the “Marquis Visit Program,”
25 or “MVP,” at the training center, where visiting surgeons have the opportunity to
26 be trained in the XLIF technique by proctors. Having a central facility for
27 demonstrating and teaching the XLIF technique to surgeons has been instrumental

1 in allowing for the safe and reproducible execution of the XLIF procedure by
2 surgeons across the country. NuVasive also began to provide local lab training for
3 surgeons without convenient access to the San Diego facilities and began to
4 facilitate peer-to-peer interaction through many different venues for surgeons to
5 discuss and observe the XLIF technique.

6 25. NuVasive also came to recognize that surgeons would be far more
7 likely to adopt XLIF if their interface with the company came from personnel that
8 not only had exhaustive knowledge of the XLIF procedure and its benefits, but
9 were also highly attuned to the unique needs and preferences of individual
10 surgeons. NuVasive first instituted a culture of “absolute responsiveness” and
11 innovation at “cheetah speed” at all levels of the company, which is still in place
12 today. This culture led to NuVasive’s unique sales representative model.

13 26. When I joined NuVasive in 2006, the company utilized mostly (if not
14 entirely) third-party, non-exclusive distributors to sell its XLIF offerings. This
15 model was widely followed by most small players in the spinal market whose
16 business was based on a limited number of customers and surgical offerings.
17 However, as more and more surgeons began seeing XLIF’s proven results and
18 adopting the procedure, NuVasive realized that it needed a different approach
19 aligned with its corporate culture of innovation and responsiveness to interface
20 with these new surgeon customers. Thus, NuVasive began using direct sales
21 representatives in conjunction with third-party sales representatives employed by
22 *exclusive* distributors; each was exhaustively trained regarding XLIF products and
23 procedure. From the beginning, this training has been intensive, and [REDACTED]

24 [REDACTED]
25 [REDACTED]
26 [REDACTED]
27 [REDACTED]. In fact,



1 NuVasive requires each and every member of the on-the-ground sales team
2 (including third party sales representatives) to demonstrate their clinical capability
3 and fluency by scoring at least 90% in a comprehensive exam. Each individual
4 trainee representative requires NuVasive to spend [REDACTED]
5 [REDACTED]. Since the beginning of its intensive sales
6 representative training efforts, NuVasive has made sure to provide surgeons with
7 easy and comprehensive access to these knowledgeable and highly-trained sales
8 people, resulting in deep relationships between surgeons in the lateral market and
9 NuVasive.

10 27. In addition, NuVasive realized it could even more effectively address
11 surgeons' skepticism if it also collected and produced data showing XLIF's
12 superiority to previous surgical procedures. To that end, NuVasive invested
13 substantial time and cost in quantifying exactly how XLIF was better than previous
14 procedures. The data showed XLIF obtained equally effective results as previous
15 procedures, but resulted in minimal loss of blood, shorter hospital stays (in some
16 cases going from three or four days in the hospital to outpatient surgery), fewer and
17 less severe complications, less post-operative pain, and quicker recovery times for
18 the patient; hospitals also incurred significantly fewer costs.

19 28. NuVasive then, and still today, made sure these results were published
20 in academic journals, presented at industry conferences, included in public filings,
21 and incorporated in marketing materials to hospitals, surgeons, and patients. Ex. 7
22 (Excerpt from 2013 NuVasive Investor Morning Transcript, Nov. 14, 2013) at 6 ("I
23 think there is no doubt that we have committed a ton of time and effort with regard
24 to clinical evidence, and so if you look at the volume of effort that has been put
25 into this, 142 journal articles, greater than 60 book chapters, 26 white papers, I
26 would tell you through – we have made a market through the publication of
27 clinical evidence that suggests that what we are doing is real."). The following are

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.